parkinsons-disease

Japan's health ministry has conditionally approved two iPS cell-derived drugs, marking the first time regenerative medicines built from induced pluripotent stem cells will reach patients commercially.

An 863-person Nature study identifies the SCAN brain network as the core driver of Parkinson's, with all four major treatments working by reducing its abnormal hyperconnectivity.